Vistagen Therapeutics (NASDAQ:VTGN) Stock Passes Below Fifty Day Moving Average – Should You Sell?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.79 and traded as low as $2.60. Vistagen Therapeutics shares last traded at $2.70, with a volume of 118,758 shares changing hands.

Vistagen Therapeutics Stock Down 2.2 %

The stock has a 50-day moving average price of $2.79 and a 200 day moving average price of $3.00. The firm has a market capitalization of $75.17 million, a PE ratio of -2.18 and a beta of 0.77.

Institutional Trading of Vistagen Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Valence8 US LP acquired a new stake in Vistagen Therapeutics in the 3rd quarter worth about $103,000. HighTower Advisors LLC purchased a new position in shares of Vistagen Therapeutics in the third quarter valued at approximately $64,000. Jane Street Group LLC acquired a new stake in shares of Vistagen Therapeutics in the third quarter worth approximately $59,000. Virtu Financial LLC increased its position in shares of Vistagen Therapeutics by 30.5% during the third quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock worth $61,000 after purchasing an additional 4,722 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in shares of Vistagen Therapeutics during the fourth quarter worth $25,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.